NeuroPhage’s GAIM Technology Chosen as ‘Top Project to Watch’ for the Therapeutic Area Partnerships Conference

Cambridge, MA, November 14, 2014 – NeuroPhage Pharmaceuticals, Inc., today announced that a panel of independent experts chose its lead project as one of the “Top Projects to Watch” for the Therapeutic Area Partnerships conference, taking place November 19-21, 2014, in Boston, MA. NeuroPhage will present a corporate overview including the Company’s lead clinical candidate NPT088 as well as its general amyloid interaction motif (GAIM) technology, which has the potential to address a broad range of diseases characterized by misfolded proteins.

GAIM recognizes a structure common to many misfolded proteins, making it suitable for development across multiple chronic neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and frontotemporal dementia, as well as peripheral diseases including the systemic amyloidoses. The approach is unique not only in its ability to target multiple types of misfolded proteins simultaneously, but also in its ability to reduce both newly forming toxic oligomers and already formed protein aggregates, providing opportunities for early- and late-stage disease treatment.

NPT088 is a fusion protein combining GAIM with a human immunoglobulin Fc region. Clinical trials are expected to start in Q4/2015. It is planned to test NPT088 in Phase 1 safety studies with Alzheimer’s disease patients, using brain imaging and biochemical markers as exploratory endpoints of efficacy.

Criteria for selection as a Top Project to Watch include: large market; large unmet need with increasing opportunity; history of the molecule and drug; strong science; strong company; diversity of indications; potential for new opportunities beyond the initial indication; and multi-level partnering opportunities.

About NeuroPhage

NeuroPhage Pharmaceuticals, Inc. is a privately funded company headquartered in Cambridge, Massachusetts.  NeuroPhage’s mission is to advance the treatment of misfolded protein diseases through GAIM therapy, simultaneously targeting multiple, toxic, misfolded proteins. NeuroPhage is initially developing drug candidates to treat Alzheimer’s and Parkinson’s diseases and several rare systemic amyloidosis diseases. 


Media Contact
Sarah Sutton
Ten Bridge Communications
518-932-3680
sarah@tenbridgecommunications.com